Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.53 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.53 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 7/20 | 0.48 |
| ▸ | WNK1 | Q9H4A3 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12415764 | 0.93 | AKR1B1 (0.49) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL2192078 | 0.91 | AKR1B1 (0.50) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL12591645 | 0.90 | AKR1B1 (0.54) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL1668253 | 0.87 | AKR1B1 (0.69) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL15984934 | 0.85 | EGFR (0.55) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL10796852 | 0.84 | EGFR (0.48) | EGFRL3MBTL1MAPT | |
| SCHEMBL8232378 | 0.83 | AKR1B1 (0.57) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL12415846 | 0.83 | EGFR (0.51) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL2653641 | 0.81 | AKR1C3 (0.79) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL4063056 | 0.79 | TDP1 (0.68) | MAPK1ALDH1A1RAB9AEGFRWNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278460-B2 | Substituted benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278460-B2 | Substituted benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278460-B2 | Substituted benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110172280-A1 | Substituted Benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172280-A1 | Substituted Benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172280-A1 | Substituted Benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2011047315-A1 | SUBSITITUTED BENZIMIDAZOLES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011047315-A1 | SUBSITITUTED BENZIMIDAZOLES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| EP-0616807-B1 | Benzimidazole useful in the treatment of central nervous system disorders | NEUROSEARCH AS (DK) | 1998-07-08 | — | — | EP | disclosed |
| US-5554632-A | CENTRAL NERVOUS SYSTEM | NEUROSEARCH A/S (DK) | 1996-09-10 | — | — | US | disclosed |
| US-5554630-A | TREATING ANXIETY, CONVULSIONS AND SLEEP DISORDERS IN LIVING ANIMALS BY MODULATION OF THE BENZODIAZEPINE RECEPTOR OF THE CENTRAL NERVOUS SYSTEM WITH 1-/3-HETEROCYCLYLPHENYL/-BENZIMIDAZOLES | NEUROSEARCH A/S (DK) | 1996-09-10 | — | — | US | disclosed |
| EP-0616807-A1 | Benzimidazole useful in the treatment of central nervous system disorders | NEUROSEARCH A/S (DK) | 1994-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172280-A1 | Substituted Benzimidazoles | GABRA5, GABRB1, GABRA4 | AKR1B1 338/4885AKR1C4 502/4885AKR1C3 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.